About

A panel of regulatory specialists, industry, and academic/medical PI's who have successfully translated technology into a First in Man trial. Discussion of international standards and US-FDA Guidances that can help provide direction to product development, manufacturing, and quality systems for First in Man experiences. Beyond knowledge, the panel will discuss the advantages and pitfalls of doing First in Man in developing countries. The panel will explore the future directions of First in Man studies and how new regulations and guidances can fit into and break the mold of current practices. The panel will discuss key considerations in determining where and how to run a First in Man or feasibility study, and how that affects global market penetration. The session will start with a 20 minute introduction on the topic, followed by panel discussion and audience interaction.

Invited Speaker(s)

Sarah E. Mische
Elaine Duncan
David Chadwick
Maureen L. Dreher, PhD

Orthopaedic Biomaterials 2

Abstracts

10:30 a.m. 137. Invited Speaker: Helen Lu, PhD
11:00 a.m. 139. NF-kB Decoy Oligodeoxynucleotide Mitigates Polyethylene Wear Particle-Induced Bone Loss but has No Effects on Exogenous Macrophage Infiltration in a Murine Continuous Femoral Particle Infusion Model, T.-H. Lin*, A. Nabeshima, J. Pajarinen, L. Cordova, F. Loi, E. Gibon, L. Lu, K. Nathan, Z. Yao, S. Goodman, Stanford University, Palo Alto, CA
11:15 a.m. 140. Particles for Osteoarthritis Treatment: Injected Wet Particulate of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid, Mechanically Cushion Joint with Long Duration, D. B. Masters*, Gel-Del Technologies, Inc, St. Paul, MN
11:30 a.m. 141. Does Metal Ion-induced Oxidative Stress Activate the Inflammasome in Macrophages?, M.-A. Ferko*, K. Kumar, I. Catelas, University of Ottawa, Ottawa, ON
11:45 a.m. 142. In Vivo Regenerative Response Enhanced In Critical Size Bone Defects Using High Performance Micro Environments, S. A. Montelongo*(1), L. Gaviria(1), J. Pearson(1), S. Stagg(1), S. Griffey(2), T. Guda(1), (1)University of Texas at SAn Antonio, San Antonio, TX, (2)Stembiosys, San Antonio, TX

Invited Speaker(s)

Helen Lu, PhD

3D Bioprinting for Medical Applications

About

3D Bioprinting for Medical Applications: 3D bioprinting is becoming widely investigated to fabricate cell-laden biomaterials and medical devices for biomedical applications. Despite this interest, limited progress has been made using 3D bioprinting as a device fabrication tool for clinical applications. This is mainly due to the lack of progress in development of novel bioprinting approaches and bioinks to create self-supporting structures with relevant scales. This session will focus on novel approaches and ink materials in 3D bioprinting.

Abstracts

10:30 a.m. 113. Invited Speaker: Ramille Shah, PhD
11:00 a.m. 115. A Generalizable Strategy for Bioprinting Hydrogels from Non-viscous Photocrosslinkable Inks to Engineer Heterogeneous Tissue Constructs, L. Ouyang(1), C. B. Highley*(1), W. Sun(2), J. A. Burdick(1), (1)University of Pennsylvania, Philadelphia, PA, (2)Tsinghua University, Beijing, China
11:15 a.m. 116. 3D Robotic Assisted Implantation of Gelatin-Nano-silicate Scaffolds for Critical Sized Bone Defect Osteogenesis and Vascularization, V. G. Varanasi*(1), T. Azimaie(1), T. Cebe(2), C. Ma(1), X. Liu(1), P. Aswath(3), (1)Texas A&M University, Dallas, TX, (2)University of Texas at Arlington, Arlington, TX, (3)Texas A&M University, Arlington, TX
11:30 a.m. 117. 3D bioprinting of perfusable intact heart, D. B. Bhuiyan*, K. Qiu, M. McAlpine, B. M. Ogle, University of Minnesota, Minneapolis, MN
11:45 a.m. 118. 3D Printed Scaffold Architecture Controls Stem Cell Differentiation, M. Guvendiren*(1), S. Fung(2), G. Vozzi(3), J. Kohn(4), (1)New Jersey Institute of Technology, Newark, NJ, (2)New Jersey Center for Biomaterials, Piscataway, NJ, (3)University of Pisa, Pisa, Italy, (4)Rutgers University, Piscataway, NJ

Invited Speaker(s)

Ramille N. Shah, PhD

Degradable Metal Biomaterials

About

Degradable Metal Biomaterials: Metal implants have traditionally been used in orthopaedic applications when strength and structural support are necessary. In many applications for which these implants have temporary function, the implant must either remain in place or be removed through a secondary surgical procedure. This session will cover topics in advances in degradable metal implants, particularly magnesium alloys, which corrode or degrade over time. Topics will include methods for assessment of degradation, biocompatibility, immune response, and mechanical properties. Novel fabrication methods or applications for degradable metal implants will include materials for use in musculoskeletal, cardiovascular, and gastrointestinal applications, among others.

Abstracts

10:30 a.m. 119. Bioresorbable rare–earth-free magnesium screws used for osteosynthesis in a sheep model, J. Eichler*(1), P. Holweg(1), L. Berger(2), M. Cihova(2), N. G. Gruen(1), N. Donohue(1), J. F. Loeffler(2), A. Weinberg(1), (1)Medical University of Graz, Graz, Austria, (2)ETH Zurich, Zurich, Switzerland
10:45 a.m. 120. 3D porous polycaprolactone-based magnesium scaffold for bone tissue engineering, K. W. K. Yeung*(1), K. Wong(1), K. Luk(1), F. Leung(1), P. Chu(2), K. Cheung(1), (1)The University of Hong Kong, Hong Kong, Hong Kong, (2)City University of Hong Kong, Hong Kong, Hong Kong
11:00 a.m. 121. Regulation of the Chronic Arterial Inflammatory Response to Biodegradable Zinc-Based Implant Materials by Corrosion, R. J. Guillory, P. K. Bowen, S. P. Hopkins, E. R. Shearier, A. A. Gillette, E. J. Earley*, E. Aghion, J. W. Drelich, J. Goldman, Michigan Technological University, Houghton, MI
11:15 a.m. 122. Porous iron-manganese-hydorxyapatite composites for biodegradable orthopaedic applications, L. Stanciu*, M. Heiden, E. Nauman, Purdue University, West Lafayette, IN
11:30 a.m. 123. Nano-surface modifications of degradable pure zinc substrates yield varying in-vivo intraluminal responses, R. J. Guillory*, E. Earley, J. Drelich, J. Goldman, Michigan Technological University, Houghton, MI
11:45 a.m. 124. Influence of strain on the corrosion of biodegradable metals, K. Beaussant Törne*(1), A. Örnberg(2), J. Weissenrieder(1), (1)Royal Institute of Technology, Kista, Sweden, (2)St Jude Medical, St. Paul, MN

Drug Delivery

About

Targeted Drug Delivery Systems: Drug delivery through traditional systemic routes results in inefficient delivery and may cause toxicity to tissue/cells distant from the target tissue. The theme of this session would be generating new biomaterials and designing unique delivery systems for targeted drug delivery. This session will invite research on novel biomaterial drug delivery systems with design elements that target specific cells, tissues, organ systems, or foreign bodies.

Abstracts

10:30 a.m. 125. PEG-poly(?-pentadecalactone-co-p-dioxanone) Nanoparticles for Intracranial Delivery of Radiosensitizing Agents, E. M. Chen*(1), A. R. King(1,2), Z. Jiang(3), R. Bindra(4), M. Saltzman(4), (1)Yale University School of Medicine, Plymouth, MN, (2)Yale University School of Engineering and Applied Science, New Haven, CT, (3)Yale University, West Haven, CT, (4)Yale Unive
10:45 a.m. 126. Erythromycin Modification to Improve the Acidic Stability while Optimizing it for Infection Site-specific Release, E. L. Cyphert*(1), H. A. von Recum(2), (1)Case Western Reserve University, Grove City, PA, (2)Case Western Reserve University, Cleveland, OH
11:00 a.m. 127. Oligonucleotide hybridized hydrogels for sustained release of small molecule (aptamer) therapeutics, N. Agrawal*(1), R. Wachs(1), Y. Du(2), P. Allen(2), A. Ellington(2), Z. Khaing(1), C. Schmidt(1), (1)University of Florida, Gainesville, FL, (2)University of Texas, Austin, TX
11:15 a.m. 128. Effect of Particle Shape and Size on Margination and Wall-localization in Vascular Drug Delivery, M. B. Cooley*(1), A. Sarode(2), S. Mitragotri(2), A. Sen Gupta(1), (1)Case Western Reserve University, Cleveland, OH, (2)University of California Santa Barbara, La Jolla, CA
11:30 a.m. 129. Enhanced Endovascular Drug Delivery and Efficacy by Linearly Micro-patterned Drug Eluting Balloon, K. J. Lee*(1), S. G. Lee(1), S. H. Park(1), Y. P. Jeon(2), M. K. Lee(2), IK Jung(2), J. S. Kim(1), WH. Ryu(1), (1)Yonsei University, Seoul, Republic of Korea, (2)GENOSS, Suwon, Republic of Korea
11:45 a.m. 130. Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by co-delivery of mRNA and sgRNA inside of synthetic lipid nanoparticles, D. Siegwart*, University of Texas Southwestern Medical Center, Dallas, TX

Engineering Cells and Their Microenvironments

Abstracts

10:30 a.m. 131. Mechanically Competent 3-D Collagen-based Tumor Extracellular Matrix Models for Investigation of Melanoma, J. Spano, T. Karpova, V. Kishore*, M. B. Fenn, Florida Institute of Technology, Melbourne, FL
10:45 a.m. 132. Directing the self-assembly of tumor spheroids within 3D bioprinted cellular heterogeneous in vitro models, T. Jiang*(1), J. G. Munguia-Lopez(2), J. Grant(1), S. Vijayakumar(1), A. De Leon-Rodriguez(2), J. M. Kinsella(1), (1)McGill University, Montreal, QC, (2)Instituto Potosino de Investigación Científica y Tecnológica (IPICyT), San Luis Potosi, Mexico
11:00 a.m. 133. Impact of VEGF Presentation and Glioblastoma on Vascularization of GelMA, M. T. Ngo*, B. A. C. Harley, University of Illinois Urbana Champaign, Urbana, IL
11:15 a.m. 134. In Situ Oxygen Delivery within Immunoisolated Devices Leads to Diabetes Reversal in an Diabetic Rodent Model, M. M. Coronel*, Y. Li, C. L. Stabler, University of Florida, Gainesville, FL
11:30 a.m. 135. Fabrication and Characterization of Vascular Smooth Muscle Cell Sheets on Enzymatic Sacrificial Hydrogel for Potential Vascular Tissue Patch Application, N. G. Rim*, A. Yih, D. Backman, J. Kim, J. Y. Wong, Boston University, Boston, MA
11:45 a.m. 136. The Use of Perfusion Flow and Co-cultures to Promote Microvessel Development in a 100% Synthetic Scaffold, M. E. E. Wright*, J. Yu, D. Jain, J. P. Santerre, University of Toronto, Toronto, ON

Supramolecular Materials for Biomedical Applications

About

Supramolecular Biomaterials: Supramolecular assemblies can range from nanocarriers to macroscale implants consisting of biological, synthetic, or hybrid materials. Their preparation using rationally designed motifs rooted in supramolecular chemistry (i.e., “chemistry beyond the molecule”) affords properties that are reversible, highly tunable, and dynamic, and as such has become an exciting new direction in the field of engineered biomaterials. The reliance on specific, non-covalent interactions affords opportunities in developing materials with “smart” functionality and activity that can be tuned in response to disease or application. Moreover, conserving the specific supramolecular motif realizes a modular approach to customize a biomaterial in a patient- or disease-specific way. These efforts have resulted in a suite of new and highly functional materials for applications in stem cell biology, regenerative medicine, drug delivery, imaging, and immunoengineering, where unique features rooted in supramolecular design give rise to important emergent properties. Examples include drug delivery, diagnostics, theranostics, tissue engineering, regenerative medicine, 3D printing, immunology, as well as use for artificial organelles and organs. Ongoing exploration in vitro up through the clinical setting has ought to validate the benefits of a supramolecular design approach.

Abstracts

10:30 a.m. 149. Designing multifunctional collagen mimetic peptides to incorporate hierarchal structure within robust hydrogel biomaterials, A. M. Hilderbrand*, C. Guo, E. Ford, A. M. Kloxin, University of Delaware, Newark, DE
10:45 a.m. 150. Modulating Cornea-mimetic Collagen Self-assembly using Artificial Chaperones, S. Majumdar*, X. Wang, S. D. Sommerfeld, Q. Guo, A. Singh, J. H. Elisseeff, Johns Hopkins University, Baltimore, MD
11:00 a.m. 151. Invited Speaker: Jason Burdick, PhD, Engineering Supramolecular Assemblies as Injectable Biomaterials
11:15 a.m. 152. Modular Peptide Amphiphile Micelles Improve an Antibody-Mediated Immune Response to Group A Streptococcus, J. Barrett*(1), B. Ulery(2), M. Tirrell(1), (1)University of Chicago, Chicago, IL, (2)University of Missouri, Columbia, MO
11:30 a.m. 153. Multifunctional Peptide Micelle for Monocyte Targeting and Gene Therapy to Reduce Atherosclerosis, E. J. Chung, M. Sarkar, C. Poon*, University of Southern California, Los Angeles, CA
11:45 a.m. 154. Development of Multivalent Protein-Conjugated GNPs as Viral Entry Inhibitors, A. M. Siehr*, B. Xu, R. A. Siegel, W. Shen, University of Minnesota, Minneapolis, MN

Invited Speaker(s)

Jason Burdick, PhD

Thought Leader Symposium - Joachim Kohn: Opportunities for Biomaterials Science in the Era of Materiomics

About

This session is designed to discuss the current state of materiomics and more specifically, biomateriomics. Discussions will include the current projects in biomateromics, challenges faced, potential solutions, and potential avenues for growth and development. The session is divided into two parts, presenations and discussion. The suffix “-omics” refers to sets of data in a given area, and the consideration of them as a whole system. Thus materiomics and biomateriomics views biomaterials as systems and studies their properties on multiple scales. We will begin with an overview given by Joachim Kohn of the New Jersey Center for Biomaterials and Rutgers University. This will outline the basic definitions of materiomics, and past work in the area, in order to lay the platform for the following presentations. Jan de Boer from Maastricht University, Netherlands will discuss his lab’s work in transcriptomics attempts to build a database cataloging transcriptomes. Carl Simon Jr of the National Institute of Standards and Technology will discuss issues in data compatibility and comparability in building the study of materiomics. William Welsh of Rutgers University will cover data requirements and uses from the computational perspective. To close out the talks, Thomas Barker of the University of Virginia will give a discussion of recent advances in synthetic biology as it applies to biomaterial design and potential future directions for the subject. Each of these talks will be 15 minutes, which will leave plenty of time for the primary goal of the session which is create a dialogue with the audience. Biomateriomics is in the beginning stages and the presenters hope that this session will spark new directions and conversations that will grow the field.

*BTI* Panel Discussion: Benchtop to Bedside: We'll Get You There! - Translating Bench Studies into First in Man Clinical Trials

About

Abstracts

Invited Speaker(s)

Orthopaedic Biomaterials 2

Abstracts

Invited Speaker(s)

3D Bioprinting for Medical Applications

About

Abstracts

Invited Speaker(s)

Degradable Metal Biomaterials

About

Abstracts

Drug Delivery

About

Abstracts

Engineering Cells and Their Microenvironments

Abstracts

Supramolecular Materials for Biomedical Applications

About

Abstracts

Invited Speaker(s)

Thought Leader Symposium - Joachim Kohn: Opportunities for Biomaterials Science in the Era of Materiomics

About

Abstracts

Invited Speaker(s)

BTI Panel Discussion: Benchtop to Bedside: We'll Get You There! - Translating Bench Studies into First in Man Clinical Trials